{"id":18543,"date":"2019-02-27T18:15:45","date_gmt":"2019-02-27T17:15:45","guid":{"rendered":"https:\/\/fundaciongaem.org\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/"},"modified":"2019-02-27T18:15:15","modified_gmt":"2019-02-27T17:15:15","slug":"sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2","status":"publish","type":"post","link":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/","title":{"rendered":"Sanitat incorpora Ocrevus\u00ae a l&#8217;SNS, primera ter\u00e0pia &#8220;efica\u00e7&#8221; per a les formes m\u00e9s freq\u00fcents d&#8217;esclerosi m\u00faltiple"},"content":{"rendered":"<h3 id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\"><span lang=\"ca\" style=\"color: #000000;\" tabindex=\"0\">Ocrevus \u00e9s el primer i \u00fanic f\u00e0rmac aprovat per l&#8217;esclerosi m\u00faltiple prim\u00e0ria progressiva, i que tamb\u00e9 \u00e9s efica\u00e7 per a les formes d&#8217;esclerosi m\u00faltiple amb brots<\/span><\/h3>\n<p>&nbsp;<\/p>\n<p id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\"><span lang=\"ca\" style=\"color: #000000;\" tabindex=\"0\">El Ministeri de Sanitat, Consum i Benestar Social ha autoritzat el finan\u00e7ament i inclusi\u00f3 d&#8217;Ocrevus\u00ae (ocrelizumab) en el Sistema Nacional de Salut (SNS). Ocrevus, comercialitzat per la farmac\u00e8utica Roche, \u00e9s el primer f\u00e0rmac aprovat que ha mostrat ser efica\u00e7 en l&#8217;esclerosi m\u00faltiple remitent recurrent (EMRR) i la secund\u00e0ria progressiva amb brots (EMSP), aix\u00ed com en la prim\u00e0ria progressiva (EMPP), les dues formes m\u00e9s freq\u00fcents de la malaltia, si b\u00e9 la EMPP representa el 10 per cent de tots els casos.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\"><span lang=\"ca\" style=\"color: #000000;\" tabindex=\"0\">Aix\u00ed ho han anunciat aquest dimarts el director de Corporate Affairs de Roche Espanya, Federico Pla\u00e7a; el cap de secci\u00f3 de Neurologia de l&#8217;Hospital General Universitari d&#8217;Alacant, \u00c1ngel P\u00e9rez Sempere; i el director del Centre d&#8217;Esclerosi M\u00faltiple de Catalunya a l&#8217;Hospital Vall d&#8217;Hebron de Barcelona i director de la Divisi\u00f3 de Neurologia de Toronto (Canad\u00e0) i del BarLo MS Centre, Xavier Montalb\u00e1n. Tots ells han destacat la import\u00e0ncia d&#8217;aquesta aprovaci\u00f3, ja que, a m\u00e9s dels beneficis que s&#8217;ha demostrat que aporta als pacients amb aquests tipus d&#8217;esclerosi m\u00faltiple, obre una finestra a futurs nous tractaments.<\/span><\/p>\n<blockquote>\n<p id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\"><span lang=\"ca\" style=\"color: #000000;\" tabindex=\"0\">&#8220;Aquest tractament suposa un pas de gegant perqu\u00e8 ha generat coneixement cient\u00edfic per a noves vies d&#8217;investigaci\u00f3&#8221;, ha afirmat Plaza.<\/span><\/p>\n<p class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\">\n<\/blockquote>\n<p>&nbsp;<\/p>\n<p>El gener de 2018 la Comissi\u00f3 Europea (CE), a trav\u00e9s de l&#8217;Ag\u00e8ncia Europea del Medicament (EMA), va autoritzar la seva comercialitzaci\u00f3 i condicions d&#8217;\u00fas a la Uni\u00f3 Europea. I el desembre de 2018, es va anunciar que ja estava disponible a Espanya com a tractament per a pacients adults amb formes recurrents d&#8217;EM activa i amb EMPP en fase primerenca, que presentessin activitat inflamat\u00f2ria en les proves d&#8217;imatge.<\/p>\n<p>&nbsp;<\/p>\n<p id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\"><span style=\"color: #000000;\"><strong><span lang=\"ca\" tabindex=\"0\">OCREVUS<\/span><\/strong><\/span><\/p>\n<p class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\"><span lang=\"ca\" style=\"color: #000000;\" tabindex=\"0\">\u00c9s el primer f\u00e0rmac modificador de la malaltia que actua selectivament eliminant les c\u00e8l\u00b7lules B CD20 +, un tipus espec\u00edfic de c\u00e8l\u00b7lules del sistema immunol\u00f2gic que tenen un paper clau en la patog\u00e8nia de l&#8217;esclerosi m\u00faltiple i contribueixen al dany de la mielina i els axons, causant discapacitat en els pacients.<\/span><\/p>\n<p class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci\u00f3\"><span lang=\"ca\" style=\"color: #000000;\" tabindex=\"0\">La forma d&#8217;administraci\u00f3 del tractament \u00e9s per via intravenosa, realitzant dues primeres infusions amb dues setmanes de difer\u00e8ncia, i les posteriors cada sis mesos, sense ser necessari efectuar controls de rutina entre dosis.<\/span><\/p>\n<p><span lang=\"ca\" style=\"color: #000000;\" tabindex=\"0\">En aquest sentit, el doctor P\u00e9rez Sempere ha assegurat que el tractament amb Ocrevus aporta tres avantatges al pacient amb esclerosi m\u00faltiple: la primera \u00e9s una alta efic\u00e0cia; la segona seguretat, \u00e9s a dir, una baixa incid\u00e8ncia d&#8217;efectes secundaris avalada per &#8220;l&#8217;experi\u00e8ncia cl\u00ednica&#8221; del seguiment durant diversos anys en els assajos cl\u00ednics; i, la tercera, la comoditat perqu\u00e8 el tractament interfereix poc en la vida quotidiana del pacient.<\/span><\/p>\n<p><a href=\"https:\/\/www.infosalus.com\/farmacia\/noticia-disponible-espana-ocrevus-roche-primera-terapia-eficaz-frente-dos-formas-mas-frecuentes-em-20190227134258.html\"><span lang=\"ca\" tabindex=\"0\">Seguir llegint la not\u00edcia en Infosalus<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000;\"><strong><span lang=\"ca\" tabindex=\"0\">Not\u00edcies relacionades:<\/span><\/strong><\/span><\/p>\n<p><span lang=\"ca\" tabindex=\"0\"><a href=\"https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-ocrelizumab-Ocrevus-esclerosis-multiple.pdf\">Informe de Posicionament Terap\u00e8utic d&#8217;ocrelizumab (Ocrevus \u00ae) en esclerosi m\u00faltiple<\/a> <span style=\"color: #000000;\">\u00b7 Ministeri de Sanitat, Consum i Benestar Social<\/span><\/span><\/p>\n<p><span lang=\"ca\" tabindex=\"0\"><a href=\"https:\/\/fundaciongaem.org\/ocrevus-nuevos-datos-eficacia-em\/\">Ocrevus (ocrelizumab): noves dades d&#8217;efic\u00e0cia i seguretat en esclerosi m\u00faltiple<\/a> <span style=\"color: #000000;\">\u00b7 Fundaci\u00f3 GAEM<\/span><\/span><\/p>\n<p><span lang=\"ca\" tabindex=\"0\"><a href=\"https:\/\/www.esclerosismultiple.com\/ocrevus-ya-en-espana\/\">Ocrevus, ja a Espanya<\/a> <span style=\"color: #000000;\">\u00b7 Esclerosi M\u00faltiple Espanya<\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ocrevus\u00ae de Roche \u00e9s el primer i \u00fanic f\u00e0rmac aprovat que ha mostrat ser efica\u00e7 en l&#8217;esclerosi m\u00faltiple remitent recurrent (EMRR) i la secund\u00e0ria progressiva amb brots (EMSP), aix\u00ed com en la Prim\u00e0ria Progressiva (EMPP), les dues formes m\u00e9s freq\u00fcents de la malaltia.<\/p>\n","protected":false},"author":1,"featured_media":17779,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[212],"tags":[2298,2168,2169,1541,1542,2144,2165,3572,2300,2104,2559,2301],"class_list":["post-18543","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-em-i-nmo","tag-empp","tag-emrr","tag-emsp","tag-esclerosi-multiple","tag-esclerosis-multiple","tag-ocrelizumab","tag-ocrevus","tag-primaria-progressiva","tag-roche","tag-sanidad","tag-sanitat","tag-sns","category-212","description-off"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sanitat incorpora Ocrevus\u00ae a l&#039;SNS, primera ter\u00e0pia &quot;efica\u00e7&quot; per a les formes m\u00e9s freq\u00fcents d&#039;esclerosi m\u00faltiple - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanitat incorpora Ocrevus\u00ae a l&#039;SNS, primera ter\u00e0pia &quot;efica\u00e7&quot; per a les formes m\u00e9s freq\u00fcents d&#039;esclerosi m\u00faltiple - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\" \/>\n<meta property=\"og:description\" content=\"Ocrevus\u00ae de Roche \u00e9s el primer i \u00fanic f\u00e0rmac aprovat que ha mostrat ser efica\u00e7 en l&#039;esclerosi m\u00faltiple remitent recurrent (EMRR) i la secund\u00e0ria progressiva amb brots (EMSP), aix\u00ed com en la Prim\u00e0ria Progressiva (EMPP), les dues formes m\u00e9s freq\u00fcents de la malaltia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/\" \/>\n<meta property=\"og:site_name\" content=\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FundacioGaem\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-27T17:15:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/fotonoticia_20190227134258_640.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"PROGRAMADOR\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@fundaciongaem\" \/>\n<meta name=\"twitter:site\" content=\"@fundaciongaem\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"PROGRAMADOR\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/\"},\"author\":{\"name\":\"PROGRAMADOR\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/person\\\/093d963705cb588ce96ffe4a15bde10c\"},\"headline\":\"Sanitat incorpora Ocrevus\u00ae a l&#8217;SNS, primera ter\u00e0pia &#8220;efica\u00e7&#8221; per a les formes m\u00e9s freq\u00fcents d&#8217;esclerosi m\u00faltiple\",\"datePublished\":\"2019-02-27T17:15:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/\"},\"wordCount\":581,\"publisher\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/fotonoticia_20190227134258_640.jpg\",\"keywords\":[\"EMPP\",\"EMRR\",\"EMSP\",\"Esclerosi M\u00faltiple\",\"Esclerosis M\u00faltiple\",\"Ocrelizumab\",\"ocrevus\",\"prim\u00e0ria progressiva\",\"roche\",\"sanidad\",\"sanitat\",\"SNS\"],\"articleSection\":[\"EM \\\/ NMO\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/\",\"name\":\"Sanitat incorpora Ocrevus\u00ae a l'SNS, primera ter\u00e0pia \\\"efica\u00e7\\\" per a les formes m\u00e9s freq\u00fcents d'esclerosi m\u00faltiple - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/fotonoticia_20190227134258_640.jpg\",\"datePublished\":\"2019-02-27T17:15:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/fotonoticia_20190227134258_640.jpg\",\"contentUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/fotonoticia_20190227134258_640.jpg\",\"width\":640,\"height\":480},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/inicio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanitat incorpora Ocrevus\u00ae a l&#8217;SNS, primera ter\u00e0pia &#8220;efica\u00e7&#8221; per a les formes m\u00e9s freq\u00fcents d&#8217;esclerosi m\u00faltiple\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/\",\"name\":\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#organization\",\"name\":\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/LOGO-2.png\",\"contentUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/LOGO-2.png\",\"width\":354,\"height\":132,\"caption\":\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\"},\"image\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/FundacioGaem\\\/\",\"https:\\\/\\\/x.com\\\/fundaciongaem\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/2454646\",\"https:\\\/\\\/www.instagram.com\\\/fundaciongaem\\\/cebook.com\\\/FundacioGaem\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/fundaciogaem\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/person\\\/093d963705cb588ce96ffe4a15bde10c\",\"name\":\"PROGRAMADOR\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g\",\"caption\":\"PROGRAMADOR\"},\"sameAs\":[\"https:\\\/\\\/fundaciongaem.org\"],\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/author\\\/gaem\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanitat incorpora Ocrevus\u00ae a l'SNS, primera ter\u00e0pia \"efica\u00e7\" per a les formes m\u00e9s freq\u00fcents d'esclerosi m\u00faltiple - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/","og_locale":"ca_ES","og_type":"article","og_title":"Sanitat incorpora Ocrevus\u00ae a l'SNS, primera ter\u00e0pia \"efica\u00e7\" per a les formes m\u00e9s freq\u00fcents d'esclerosi m\u00faltiple - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","og_description":"Ocrevus\u00ae de Roche \u00e9s el primer i \u00fanic f\u00e0rmac aprovat que ha mostrat ser efica\u00e7 en l'esclerosi m\u00faltiple remitent recurrent (EMRR) i la secund\u00e0ria progressiva amb brots (EMSP), aix\u00ed com en la Prim\u00e0ria Progressiva (EMPP), les dues formes m\u00e9s freq\u00fcents de la malaltia.","og_url":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/","og_site_name":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","article_publisher":"https:\/\/www.facebook.com\/FundacioGaem\/","article_published_time":"2019-02-27T17:15:45+00:00","og_image":[{"width":640,"height":480,"url":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/fotonoticia_20190227134258_640.jpg","type":"image\/jpeg"}],"author":"PROGRAMADOR","twitter_card":"summary_large_image","twitter_creator":"@fundaciongaem","twitter_site":"@fundaciongaem","twitter_misc":{"Escrit per":"PROGRAMADOR","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/#article","isPartOf":{"@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/"},"author":{"name":"PROGRAMADOR","@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/person\/093d963705cb588ce96ffe4a15bde10c"},"headline":"Sanitat incorpora Ocrevus\u00ae a l&#8217;SNS, primera ter\u00e0pia &#8220;efica\u00e7&#8221; per a les formes m\u00e9s freq\u00fcents d&#8217;esclerosi m\u00faltiple","datePublished":"2019-02-27T17:15:45+00:00","mainEntityOfPage":{"@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/"},"wordCount":581,"publisher":{"@id":"https:\/\/fundaciongaem.org\/ca\/#organization"},"image":{"@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/#primaryimage"},"thumbnailUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/fotonoticia_20190227134258_640.jpg","keywords":["EMPP","EMRR","EMSP","Esclerosi M\u00faltiple","Esclerosis M\u00faltiple","Ocrelizumab","ocrevus","prim\u00e0ria progressiva","roche","sanidad","sanitat","SNS"],"articleSection":["EM \/ NMO"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/","url":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/","name":"Sanitat incorpora Ocrevus\u00ae a l'SNS, primera ter\u00e0pia \"efica\u00e7\" per a les formes m\u00e9s freq\u00fcents d'esclerosi m\u00faltiple - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","isPartOf":{"@id":"https:\/\/fundaciongaem.org\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/#primaryimage"},"image":{"@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/#primaryimage"},"thumbnailUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/fotonoticia_20190227134258_640.jpg","datePublished":"2019-02-27T17:15:45+00:00","breadcrumb":{"@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/#primaryimage","url":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/fotonoticia_20190227134258_640.jpg","contentUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/fotonoticia_20190227134258_640.jpg","width":640,"height":480},{"@type":"BreadcrumbList","@id":"https:\/\/fundaciongaem.org\/ca\/sanitat-incorpora-ocrevus-a-lsns-primera-terapia-eficac-per-a-les-formes-mes-frequents-desclerosi-multiple-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fundaciongaem.org\/ca\/inicio\/"},{"@type":"ListItem","position":2,"name":"Sanitat incorpora Ocrevus\u00ae a l&#8217;SNS, primera ter\u00e0pia &#8220;efica\u00e7&#8221; per a les formes m\u00e9s freq\u00fcents d&#8217;esclerosi m\u00faltiple"}]},{"@type":"WebSite","@id":"https:\/\/fundaciongaem.org\/ca\/#website","url":"https:\/\/fundaciongaem.org\/ca\/","name":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","description":"","publisher":{"@id":"https:\/\/fundaciongaem.org\/ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fundaciongaem.org\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/fundaciongaem.org\/ca\/#organization","name":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","url":"https:\/\/fundaciongaem.org\/ca\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2023\/11\/LOGO-2.png","contentUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2023\/11\/LOGO-2.png","width":354,"height":132,"caption":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)"},"image":{"@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/FundacioGaem\/","https:\/\/x.com\/fundaciongaem","https:\/\/www.linkedin.com\/company\/2454646","https:\/\/www.instagram.com\/fundaciongaem\/cebook.com\/FundacioGaem\/","https:\/\/www.youtube.com\/user\/fundaciogaem"]},{"@type":"Person","@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/person\/093d963705cb588ce96ffe4a15bde10c","name":"PROGRAMADOR","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g","caption":"PROGRAMADOR"},"sameAs":["https:\/\/fundaciongaem.org"],"url":"https:\/\/fundaciongaem.org\/ca\/author\/gaem\/"}]}},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/posts\/18543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/comments?post=18543"}],"version-history":[{"count":0,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/posts\/18543\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/media\/17779"}],"wp:attachment":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/media?parent=18543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/categories?post=18543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/tags?post=18543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}